Literature DB >> 10312123

Economic evaluation and the rational diffusion and use of health technology.

M F Drummond.   

Abstract

In principle, economic evaluation provides a suitable framework for the assessment of the costs and benefits of health technologies. However, despite a rapid growth in the publication of cost-effectiveness and cost-benefit analysis in health care, there is little evidence that economic evaluation has yet become part of an integrated approach to technology assessment. This paper, based on the findings of a European Community project on economic appraisal of health technology, discusses how the design and conduct of economic evaluations can be improved so as to increase their relevance to health care decision making, and how policies on the diffusion and use of health technology can be devised so as to make fuller use of the economic evaluations that are carried out.

Mesh:

Year:  1987        PMID: 10312123     DOI: 10.1016/0168-8510(87)90072-8

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  9 in total

1.  The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life.

Authors:  G Hawthorne; J Richardson; R Osborne
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

2.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

3.  Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992       Impact factor: 4.981

4.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

5.  The cost-effectiveness of orphan drugs.

Authors:  M C Weinstein
Journal:  Am J Public Health       Date:  1991-04       Impact factor: 9.308

6.  Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease.

Authors:  J W Hay; E D Robin
Journal:  Am J Public Health       Date:  1991-04       Impact factor: 9.308

7.  Economic evaluations of health technologies in Dutch healthcare decision-making: a qualitative study of the current and potential use, barriers, and facilitators.

Authors:  Kitty J Roseboom; Johanna M van Dongen; Emile Tompa; Maurits W van Tulder; Judith E Bosmans
Journal:  BMC Health Serv Res       Date:  2017-01-26       Impact factor: 2.655

8.  Bridging the gap between the economic evaluation literature and daily practice in occupational health: a qualitative study among decision-makers in the healthcare sector.

Authors:  Johanna M van Dongen; Emile Tompa; Laurie Clune; Anna Sarnocinska-Hart; Paulien M Bongers; Maurits W van Tulder; Allard J van der Beek; Marieke F van Wier
Journal:  Implement Sci       Date:  2013-06-03       Impact factor: 7.327

9.  Epistemic communities and experts in health policy-making.

Authors:  Olga Löblová
Journal:  Eur J Public Health       Date:  2018-11-01       Impact factor: 3.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.